Chun-Hsiang Lai

Chun-Hsiang Lai

Auto-generated profile, based on publicly available information

Chun-Hsiang Lai

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
TGTona M. Gilmer
Tona M. Gilmer
CLChun-Hsiang Lai
Chun-Hsiang Lai
KGKexiao Guo
Kexiao Guo
KDKatherine Deland
Katherine Deland
KAKathleen A. Ashcraft
Kathleen A. Ashcraft
MKMichael Kastan
Michael Kastan
A majority of patients with cancer receive radiotherapy as part of their treatment regimens whether using external beam therapy or locally-delivered radioisotopes. While often effective, some tumors are inadequately controlled with radiation and radiotherapy has significant short-term and long-term toxicities for cancer survivors. Insights into molecular mechanisms involved in cellular responses to DNA breaks introduced by radiation or other cancer therapies have been gained in recent years and approaches to manipulate these responses to enhance tumor cell killing or reduce normal tissue toxicity are of great interest. Here, we report the identification and initial characterization of XRD-0394, a potent and specific dual inhibitor of two DNA damage response kinases, ATM and DNA-PKcs. This orally bioavailable molecule demonstrates significantly enhanced tumor cell kill in the setting of therapeutic ionizing irradiation in vitro and in vivo. XRD-0394 also potentiates the effectiveness of topoisomerase I inhibitors in vitro. In addition, in cells lacking BRCA1/2 XRD-0394 shows single-agent activity and synergy in combination with PARP inhibitors. A phase Ia clinical trial (NCT05002140) with XRD-0394 in combination with radiotherapy has completed. These results provide a rationale for future clinical trials with XRD-0394 in combination with radiotherapy, PARP inhibitors, and targeted delivery of topoisomerase I inhibitors.


4 June 2024
Verified
Other
Open access
TGTona M. Gilmer
Tona M. Gilmer
CLChun-Hsiang Lai
Chun-Hsiang Lai
KGKexiao Guo
Kexiao Guo
KDKatherine Deland
Katherine Deland
KAKathleen A. Ashcraft
Kathleen A. Ashcraft
MKMichael Kastan
Michael Kastan
MCF7 clonogenic survival treated with XRD-0394

4 June 2024
Verified
Other
Open access
TGTona M. Gilmer
Tona M. Gilmer
CLChun-Hsiang Lai
Chun-Hsiang Lai
KGKexiao Guo
Kexiao Guo
KDKatherine Deland
Katherine Deland
KAKathleen A. Ashcraft
Kathleen A. Ashcraft
MKMichael Kastan
Michael Kastan
MDA-MB-231 clonogenic survival treated with XRD-0394


4 June 2024
Verified
Other
Open access
TGTona M. Gilmer
Tona M. Gilmer
CLChun-Hsiang Lai
Chun-Hsiang Lai
KGKexiao Guo
Kexiao Guo
KDKatherine Deland
Katherine Deland
KAKathleen A. Ashcraft
Kathleen A. Ashcraft
MKMichael Kastan
Michael Kastan
FaDu clonogenic survival treated with XRD-0394